• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
  • Development Programs
    • Biopharmaceutical Trials
    • Combination Therapy
    • Pathways to Commercialisation
    • Mente Technology
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Company Reports
    • Presentations
    • Research
    • News & Media
  • Contact

Improving Lives

Focusing on the development and commercialisation of neurological solutions

Learn More

ASX:NTI

Exclusive worldwide licence

Extensive preclinical studies completed

Neurotech’s Mente device and therapy

World’s first whole plant extract cannabis clinical study

Potential for NTI164 to treat neurological disorders

PTC Patents lodged

Neurotech is a biopharmaceutical company focused on the development & commercialisation of neurological solutions that improve quality of life. NTI’s current focus is their world-first clinical study utilising NTI164 in the treatment for paediatric Autism Spectrum Disorder (ASD).

 The Company is also focused on commercialising Mente, the world’s first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

Learn More

Bioshares Report
Now Available

Neurotech International (NTI: $0.071) has released the results from its Phase II study in children with moderate autismspectrumdisorder (ASD). The study involved 14 children who were treated with the proprietarymedicinal cannabis strain which contains less than 0.3% THC, which is the main psychoactive constituent of cannabis.

Read Full Report

Latest Announcements

Latest News

  • 4RO

    Gerald Quigley, short discussion on 4RO Rockhampton regarding Autism

    02 Aug 2022
  • 6PR

    Gerald Quigley, Co-host of The House of Wellness on 6PR discusses exciting new developments in Autism Spectrum Disorder (ASD) field linked to Cannabis, including a particular extract called NTI164.

    30 Jul 2022
  • Stocks Down Under

    Stocks Down Under Interview with Neurotech International (ASX:NTI)

    27 Jul 2022
  • Stockhead

    Neurotech eyes Phase II/III trial and FDA approval after cannabis breakthrough on paediatric autism

    22 Jul 2022

Footer

Suite 5 CPC, 145 Stirling Highway
Nedlands WA 6009
Australia

moc.l1660026060anoit1660026060anret1660026060nihce1660026060torue1660026060n@ofn1660026060i1660026060

+61 (8) 9389 3130

Subscribe to our latest announcements

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2022 Neurotech International • Site by White Noise Communications

Download prospectus